ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANI Pharmaceuticals reported Q2 adjusted EPS of $2.21 and revenue of $266M, both above consensus. Cortrophin Gel revenue rose 43.5% to $117.1M but missed $120.4M. For 2026, ANI cut Cortrophin guidance to $520-$540M from $540-$575M while keeping total revenue $1.08-$1.14B and EPS $9.19-$9.69.
How this was made
The 30-second read
Why it matters
The key trading issue is whether Cortrophin can accelerate in the second half enough to meet the revised 2026 range, given the first-half base and the implied back-half concentration.
Market read
A guidance cut to the primary growth engine, paired with a Q2 miss, raises the probability of near-term volatility around sequential Cortrophin prints.
What to watch
The article notes gout sales force ramp progress (95% of new reps generating multiple cases) and prescriber conversion signals, which could support a faster-than-guidance catch-up in Q4.
Background
ANI’s growth mix is increasingly dependent on Cortrophin Gel, and the quarter showed a divergence between overall beats and Cortrophin underperformance.
Ticker impact
ANI reported Q2 EPS and revenue beats, but Cortrophin Gel revenue missed consensus and management cut 2026 Cortrophin guidance to $520-$540M.
Near-term downside bias as investors reprice the probability of another Cortrophin shortfall versus the unchanged full-year framework.
The article discloses a specific guidance reduction for the key growth driver (Cortrophin) plus a miss versus consensus, raising the bar for back-half sequential growth.
Market effects
Rare-disease commercial execution risk is highlighted, potentially affecting sentiment toward other specialty pharma growth drivers tied to patient-case conversion.
No specific regional impact described.
No specific global catalyst described.
Counterpoint
The company kept total revenue, EBITDA, and EPS guidance unchanged, implying management believes the broader model can absorb Cortrophin variability without a full reset.
Key entities
- companyANI Pharmaceuticals, Inc.
Reported Q2 beat but cut 2026 Cortrophin revenue guidance; next test is Q3 Cortrophin revenue ($143-$153M).
- productCortrophin Gel
Gout-focused therapy and ANI’s key growth driver; guidance was lowered and it missed Q2 consensus.
- productIluvien
Retina business with 2026 revenue guidance maintained at $78-$83M.
- business segmentGenerics
Generated $204.5M in first half 2026 and supports companywide outlook alongside Iluvien.
